| Literature DB >> 34286473 |
Eun-Joo Shin1, Ji Hoon Jeong2, Yeonggwang Hwang1, Naveen Sharma1,2, Duy-Khanh Dang1,3, Bao-Trong Nguyen1, Seung-Yeol Nah4, Choon-Gon Jang5, Guoying Bing6, Toshitaka Nabeshima7, Hyoung-Chun Kim8,9.
Abstract
Parkinson's disease (PD) is a progressive neurodegenerative disease with a high prevalence, approximately 1 % in the elderly population. Numerous studies have demonstrated that methamphetamine (MA) intoxication caused the neurological deficits and nigrostriatal damage seen in Parkinsonian conditions, and subsequent rodent studies have found that neurotoxic binge administration of MA reproduced PD-like features, in terms of its symptomatology and pathology. Several anti-Parkinsonian medications have been shown to attenuate the motor impairments and dopaminergic damage induced by MA. In addition, it has been recognized that mitochondrial dysfunction, oxidative stress, pro-apoptosis, proteasomal/autophagic impairment, and neuroinflammation play important roles in inducing MA neurotoxicity. Importantly, MA neurotoxicity has been shown to share a common mechanism of dopaminergic toxicity with that of PD pathogenesis. This review describes the major findings on the neuropathological features and underlying neurotoxic mechanisms induced by MA and compares them with Parkinsonian pathogenesis. Taken together, it is suggested that neurotoxic binge-type administration of MA in rodents is a valid animal model for PD that may provide knowledge on the neuropathogenesis of PD.Entities:
Keywords: Animal model; Dopaminergic neurotoxicity; Methamphetamine; Parkinson’s disease
Mesh:
Substances:
Year: 2021 PMID: 34286473 DOI: 10.1007/s12272-021-01341-7
Source DB: PubMed Journal: Arch Pharm Res ISSN: 0253-6269 Impact factor: 4.946